Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia

Applied Immunohistochemistry and Molecular Morphology

Volumn 20, Issue 3, 2012, Pages 264-271

  Edgecombe, Allison ^a   Nguyen, Bich N ^a   Djordjevic, Bojana ^a   Belanger, Eric C ^a   Mai, Kien T ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

carcinoma; cytokeratin 5 6; urinary bladder

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 5; CYTOKERATIN 6; PROTEIN P16;

ARTICLE; BASEMENT MEMBRANE; CANCER GRADING; CARCINOMA IN SITU; CLINICAL ARTICLE; CLINICAL FEATURE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PAPILLARY CARCINOMA; PAPILLARY UROTHELIAL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REACTIVE UROTHELIAL ATYPIA; SQUAMOUS EPITHELIUM; THICKNESS; TRANSITIONAL CELL CARCINOMA; TUMOR DIFFERENTIATION; UROTHELIAL CARCINOMA IN SITU; UROTHELIUM;

BIOPSY; CARCINOMA IN SITU; CARCINOMA, PAPILLARY; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; KERATIN-5; KERATIN-6; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84859900445     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182351ed3     Document Type: Article

References (39)

1. Moll R, Franke WW, Schiller DL, et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11-24. (Pubitemid 13215192)
2. Miettinen M. Keratin immunohistochemistry: update of applications and pitfalls. Pathol Annu. 1993;28:113-143.
3. Cooper D, Schermer A, Sun TT. Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications, and limitations. Lab Invest. 1985;2:243-256. (Pubitemid 15144079)
4. Cury PM, Butcher DN, Fisher CM, et al. Value of the mesotheliumassociated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol. 2000; 13:107-112. (Pubitemid 30109095)
5. Ordó nez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006; 19:417-428. (Pubitemid 43276996)
6. Abrahams NA, Bostwick DG, Ormsby AH, et al. Distinguishing atrophy and high-grade prostatic intraepithelial neoplasia from prostatic adenocarcinoma with and without previous adjuvant hormone therapy with the aid of cytokeratin 5/6. Am J Clin Pathol. 2003;120:368-376. (Pubitemid 37295106)
7. Abrahams NA, Ormsby AH, Brainard J. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies. Histopathology. 2002;41:35-41. (Pubitemid 34779679)
8. Paner GP, Luthringer DJ, Amin MB. Best practice in diagnostic immunohistochemistry: prostate carcinoma and its mimics in needle core biopsies. Arch Pathol Lab Med. 2008;132:1388-1396.
9. Otterbach F, Bà nkfalvi A, Bergner S, et al. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology. 2000;37:232-240.
10. MacGrogan G, Arnould L, de Mascarel I, et al. Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions. Histopathology. 2008;52:689-697. (Pubitemid 351600053)
11. Vlasoff DM, Baschinsky DY, Frankel WL. Cytokeratin 5/6 immunostaining in hepatobiliary and pancreatic neoplasms. Appl Immunohistochem Mol Morphol. 2002;10:147-151. (Pubitemid 34553171)
12. Long KB, Hornick JL. SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract. Hum Pathol. 2009;40: 1768-1773.
13. Hodges KB, Lopez-Beltran A, Davidson DD, et al. Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum Pathol. 2010;41:155-156.
14. Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A. 2009;106:14016-14021.
15. Eissa S, Zohny SF, Swellam M, et al. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer. Clin Biochem. 2008;41:1335-1341.
16. Russo S, Botti G, Vinaccia P, et al. A useful panel in proliferative urothelial lesions: an analysis of cytokeratin 20, p53, CD44 and Ki- 67 antigens. Pathologica. 2007;99:46-49. (Pubitemid 350186359)
17. McKenney JK, Desai S, Cohen C, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and nonneoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001;25:1074-1078. (Pubitemid 32685906)
18. Droller MJ. Markers in bladder cancer-issues to consider. J Urol. 1998;160(6 Pt 1):2009-2010.
19. Desai S, Lim SD, Jimenez RE, et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol. 2000;13:1315-1323. (Pubitemid 32014669)
20. Yin H, Leong AS. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998WHO/ISUP system by immunophenotyping and follow-up. Am J Clin Pathol. 2004;121:679-687. (Pubitemid 38534000)
21. Ramos D, Navarro S, Villamón R, et al. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder. Cancer. 2003;97:1876-1883. (Pubitemid 36397261)
22. Alsheikh A, Mohamedali Z, Jones E, et al. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology. Mod Pathol. 2001;14:267-272. (Pubitemid 32298910)
23. Pan CC, Chang YH, Chen KK, et al. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1515 cases. Am J Clin Pathol. 2010;133:788-795.
24. Krüger S, Thorns C, Böhle A, et al. Prognostic significance of a grading system considering tumor heterogeneity in muscle-invasive urothelial carcinoma of the urinary bladder. Int Urol Nephrol. 2003;35:169-173. (Pubitemid 38418210)
25. Samaratunga H, Makarov DV, Epstein JI. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology. 2002;60:315-319. (Pubitemid 34831779)
26. Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch. 2002;441:105-108. (Pubitemid 34983975)
27. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, et al. Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems. J Clin Pathol. 2002;55:900-905. (Pubitemid 35454490)
28. Miyamoto H, Miller JS, Fajardo DA, et al. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int. 2010;60:1-8.
29. Campbell PA, Conrad RJ, Campbell CM, et al. Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome. BJU Int. 2004;93:1228-1231. (Pubitemid 38823942)
30. Yorukoglu K, Tuna B, Dikicioglu E, et al. Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder. Virchows Arch. 2003;443:734-740. (Pubitemid 38030626)
31. Miyamoto H, Brimo F, Schultz L, et al. Low-grade papillary urothelial carcinoma of the urinary bladder: a cinicopathologic analysis of a post-World Health Organization/International ociety of Urological Pathology classification cohort from a single academic center. Arch Pathol Lab Med. 2010;134:1160-1163.
32. Gonul II, Poyraz A, Unsal C, et al. Comparison of 1998 WHO/ISUP and 1973 WHO classifications for interobserver variability in grading of papillary urothelial neoplasms of the bladder. Pathological evaluation of 258 cases. Urol Int. 2007;78: 338-344. (Pubitemid 46725706)
33. Mamoon N, Iqbal MA, Jamal S, et al. Urothelial neoplasia of the urinary bladder-comparison of interobserver variability for WHO Classification 1972 with WHO/ISUP Consensus Classification 1998. J Ayub Med Coll Abbottabad. 2006;18:4-8.
34. Kunju LP, Lee CT, Montie J, et al. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Pathol Int. 2005;55: 248-254. (Pubitemid 40827463)
35. Yin M, Bastacky S, Parwani AV, et al. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. Hum Pathol. 2008;39:527-535.
36. Holmäng S, Johansson SL. Urothelial carcinoma of the upper urinary tract:comparison between the WHO/ISUP 1998 consensus classification and WHO 1999 classification system. Urology. 2005; 66:274-278. (Pubitemid 41138081)
37. Kaplan I, Vered M, Moskona D, et al. An immunohistochemical study of p53 and PCNA in inflammatory papillary hyperplasia of the palate: a dilemma of interpretation. Oral Dis. 1998;4:194-199. (Pubitemid 28427803)
38. Sugino T, Gorham H, Yoshida K, et al. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol. 1996; 149:873-882. (Pubitemid 26334171)
39. Liegl B, Regauer S. p53 immunostaining in lichen sclerosus is related to ischaemic stress and is not a marker of differentiated vulvar intraepithelial neoplasia (d-VIN). Histopathology. 2006;48: 268-274.